Abstract
The half-life of the 18F isotope is the highest among all the positron-emitting isotopes, and therefore positron emission tomography (PET) using 18F-labeled pharmaceuticals has practical advantage in the clinical settings. There are currently four 18F-labeled PET imaging agents approved by the Food and Drug Administration: [18F]-2-fluoro-2-deoxyglucose (18F-FDG), Florbetapir-18F ([18F]AV-45), florbetaben-18F (Neuraceq; BAY 94-9172), and flutemetamol-18F (Vizamyl). 18F-FDG is useful for monitoring the glucose metabolism, while the remaining three tracers are designed to monitor the levels of amyloid plaques in the brains of patients suffering from Alzheimer's- and Parkinson disease and epilepsy. Many more 18F-labeled pharmaceuticals are in clinical trials for human PET imaging. This chapter outlines the recent developments in the synthesis and applications of the 18F-labeled PET tracers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
